Drug Overview
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).
Twice-daily Advair was the first ICS/LABA combination to launch and quickly became the gold standard in its class and across the asthma and COPD markets. It was first launched for asthma in the UK in 1999 and was rolled out in the rest of Europe in 2000–01 and in the US in 2001. It became available in Japan in 2007. While the majority of sales are for asthma, the drug is a blockbuster for COPD as well.
Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).
Twice-daily Advair was the first ICS/LABA combination to launch and quickly became the gold standard in its class and across the asthma and COPD markets. It was first launched for asthma in the UK in 1999 and was rolled out in the rest of Europe in 2000–01 and in the US in 2001. It became available in Japan in 2007. While the majority of sales are for asthma, the drug is a blockbuster for COPD as well.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
